Back

Complication comparison in intermediate-to-high risk venous thromboembolism patients, treated with high vs standard dose apixaban and rivaroxaban after low molecular weight heparin

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Pearls of acute pulmonary embolism Venous Thromboembolism ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Anton Kristoffer Garner

Slagelse Hospital, Slagelse (Denmark)

7 More presentations in this session

Presentation thumbnail
Epidemiology of acute pulmonary embolism in children and adolescents from nationwide US hospital data, 2016 and 2019
Mr S. Wolf (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
A simple and reliable computed tomographic measure for the evaluation of right ventricle remodelling in acute PE: right ventricle apical angle
Doctor B. Kultursay (Tunceli, TR)
Abstract Slides Video
Presentation thumbnail
A novel dynamic risk score to predict venous thromboembolism (VTE) recurrences after 3 months of anticoagulation in patients with incident VTE and without active cancer.
Doctor A. Cohen (London, GB)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of long-term edoxaban treatment for low body weight cancer patients with isolated distal deep vein thrombosis: a post-hoc subgroup analysis of the ONCO DVT study
Doctor T. Nagai (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Baseline characteristics, management patterns and outcome in patients with pulmonary embolism and malignancy: Insights from a single-centre study
Doctor H. Tokgoz (Istanbul, TR)
Abstract Slides Video

Access the full session

Session thumbnail
Pearls of acute pulmonary embolism

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Clinical outcomes of edoxaban treatment without parenteral anticoagulation therapy for acute venous thromboembolism: Insight from the COMMAND VTE Registry-2
thumbnail
Congress Presentation
Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation
thumbnail
Congress Presentation
A novel dynamic risk score to predict venous thromboembolism (VTE) recurrences after 3 months of anticoagulation in patients with incident VTE and without active cancer.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources